GlassScriptPhysician profile
Veling W Tsai
NPI 1619190378
$2,644.42
in general payments reported to CMS, 2019-2025
13 companies · $685 in 2025
The $685 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $150 · 2021: $121 · 2022: $344 · 2023: $463 · 2024: $415 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,563.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $779.87 | 2019-2025 | |
| Glaxosmithkline, LLC. | $527.78 | 2023-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $401.82 | 2022-2025 | Dupixent |
| Genzyme Corporation | $365.37 | 2022-2025 | |
| Intersect Ent, INC. | $197.22 | 2019-2021 | |
| Stryker Corporation | $119.51 | 2019-2021 | |
| Hikma Pharmaceuticals USA | $67.36 | 2022-2023 | Ryaltris |
| Acclarent, INC | $57.46 | 2019-2023 | Trudi Nav Cable, Relieva Spinplus |
| Astrazeneca Pharmaceuticals LP | $50.63 | 2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $24.00 | 2019 | |
| Lilly USA, LLC | $22.73 | 2025 | Zepbound |
| Integra Lifesciences Corporation | $18.67 | 2025 | Inspira Air, Acclarent Aera, Relieva Spinplus Nav |
| Glenmark Therapeutics INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veling Tsai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.